Inspira™ Receives Israeli Regulatory Approval for the INSPIRA™ ART100 System
Inspira Technologies has received approval from the Israeli Ministry of Health for its INSPIRA™ ART100 system, an Extra-Corporeal Membrane Oxygenation and Cardiopulmonary Bypass system. This approval follows the FDA clearance announced on May 28, 2024.
Both approvals are critical milestones, enhancing the company's market opportunities in the U.S. and Israel. The INSPIRA™ ART100, equipped with Adaptive Blood Oxygenation technology, measures blood parameters in real-time to deliver oxygen directly into the blood.
CEO Dagi Ben-Noon and Dr. Dekel Stavi highlight the significance of these approvals for business expansion and local adoption. The company aims to revolutionize respiratory and life-support technologies with further product development, although some products like the INSPIRA™ ART (Gen 2) and HYLA™ blood sensor remain untested and unapproved by any regulatory bodies.
- Israeli Ministry of Health approval for INSPIRA™ ART100.
- FDA clearance for INSPIRA™ ART100 on May 28, 2024.
- Opens market opportunities in the U.S. and Israel.
- Features Adaptive Blood Oxygenation technology for real-time blood parameter monitoring.
- INSPIRA™ ART (Gen 2) and HYLA™ blood sensor remain untested and unapproved.
Inspira Technologies' approval from the Israeli Ministry of Health for the INSPIRA™ ART100 system is a significant step in their journey. This technology, which includes Extra-Corporeal Membrane Oxygenation (ECMO) and Cardiopulmonary Bypass capabilities, is designed to elevate patient oxygen levels rapidly, potentially allowing patients to remain conscious during treatment. This can offer a revolutionary shift in how critical respiratory care is administered.
From a research perspective, the real-time blood parameter monitoring embedded in the ART100 system is particularly noteworthy. This feature provides continuous data, which can lead to better patient outcomes through timely interventions. However, the system's efficacy and safety in real-world settings remain to be fully validated, especially beyond controlled environments like intensive care units.
For investors, it's important to note that while the ART100 has received regulatory clearance, other products in Inspira's pipeline, such as the INSPIRA™ ART500 and HYLA™ blood sensor, are still in the early stages. These products have not yet undergone human testing or received regulatory approval, representing both an opportunity and a risk, depending on future clinical outcomes.
The recent approval by the Israeli Ministry of Health for the INSPIRA™ ART100 system follows the earlier FDA clearance, positioning Inspira Technologies for potential market expansion. This regulatory milestone can drive
From a financial perspective, this approval underpins the company's strategy to enter new markets. However, investors should weigh this against the company's current stage. Early-stage companies like Inspira, especially in the medical technology sector, face inherent risks such as prolonged commercialization timelines and the necessity for substantial capital expenditure to scale production and distribution.
Short-term, this approval might boost investor sentiment and share price valuation. In the long-term, sustained profitability will depend on the successful commercialization of their broader product portfolio, which is still under development and unapproved for human use.
The AMAR approval for the INSPIRA™ ART100 system marks a important step for Inspira Technologies in establishing its footprint in the Israeli medical devices market. The ECMO and Cardiopulmonary Bypass technologies embedded in the ART100 address a critical need in respiratory and cardiac care, which can potentially drive high adoption rates among hospitals.
However, the competitive landscape in the medical devices market is intense. Inspira's success will largely depend on their ability to differentiate their products from existing solutions. Their real-time blood monitoring feature is a potential differentiator, but the market's response will be the ultimate test. Additionally, strategic alliances and partnerships could play a pivotal role in accelerating market penetration and ensuring sustained growth.
Long-term market success will require ongoing innovation and robust post-market surveillance to ensure the technology meets clinical expectations and addresses any safety concerns that may arise.
Approval follows the FDA clearance announced on May 28, 2024
RA'ANANA,
![Inspira Technologies Logo Inspira Technologies Logo](https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg)
The Company believes that receiving Israeli regulatory approval marks an important step towards growing local support and adoption for the INSPIRA™ ART100 and demonstrates Inspira's capabilities in obtaining regulatory approvals for its products.
Dr. Dekel Stavi, head of the Israeli Extra-Corporeal Membrane Oxygenation ("ECMO") Society and Inspira's Medical Director, commented, "As a physician and the head of the Israeli ECMO Society, I am delighted to witness this exciting milestone where hospitals will have the opportunity to acquire and use the innovative and technologically cutting-edge INSPIRA™ ART100."
Dagi Ben-Noon, CEO of Inspira Technologies, stated, "After we received FDA approval for the INSPIRA ART100 that will allow us to establish our presence in the
Inspira Technologies OXY B.H.N. Ltd.
Inspira™ Technologies targets to reshape the respiratory and life-support landscape. We are developing novel expanding life support technologies and solutions to prolong life and improve the quality of life for patients. Inspira is on a quest to become the leading ground-breaking medical device company in our field with business alliances around the world.
The INSPIRA™ ART (Gen 2), also known as the INSPIRA™ ART500, will include the Company's Adaptive Blood Oxygenation technology and is being designed to continuously measure the patient's blood parameters in real-time, delivering needed oxygen volume straight into the blood. By elevating patient oxygen saturation levels in minutes, this technology potentially allows patients to remain awake during treatment and therefore may enable patients to be treated in and beyond intensive care units, reducing the need for mechanical ventilation systems that require intubation and medically induced coma.
The Company's INSPIRA™ ART100 system received FDA 510(k) clearance for Cardiopulmonary Bypass procedures and AMAR certification for Extra-Corporeal Membrane Oxygenation and Cardiopulmonary Bypass procedures.
The Company's other products, including the INSPIRA™ ART (Gen 2) and HYLA™ blood sensor, have not yet been tested or used in humans and have not been approved by any regulatory entity.
For more information, please visit our corporate website: https://inspira-technologies.com
Forward-Looking Statement Disclaimer
This press release contains express or implied forward-looking statements pursuant to
For more details:
Public Relations Manager
Adi Shmueli
Inspira Technologies
info@inspirao2.com
+972-9-9664485
Copyright © 2018-2024 Inspira Technologies OXY B.H.N. LTD., All rights reserved.
Logo: https://mma.prnewswire.com/media/1668495/Inspira_Technologies_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/inspira-receives-israeli-regulatory-approval-for-the-inspira-art100-system-302194789.html
SOURCE Inspira Technologies
FAQ
What recent approvals has Inspira Technologies received for the INSPIRA™ ART100?
What is the INSPIRA™ ART100 system?
When did the INSPIRA™ ART100 receive FDA clearance?
How will the INSPIRA™ ART100 system affect business opportunities for Inspira Technologies?